Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer

被引：0
|
作者：
Sung Gwe Ahn
Yoon Jin Cha
Soon June Bae
Chanik Yoon
Hak Woo Lee
Joon Jeong
机构：
[1] Yonsei University College of Medicine,Department of Surgery, Gangnam Severance Hospital
[2] Yonsei University College of Medicine,Department of Pathology, Gangnam Severance Hospital
来源：
BMC Cancer | / 18卷
关键词：
Tumor-infiltrating lymphocytes; 21-gene recurrence score; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
    Sandra M. Swain
    Raquel Nunes
    Carl Yoshizawa
    Megan Rothney
    Amy P. Sing
    Advances in Therapy, 2015, 32 : 1222 - 1236
  • [22] Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
    Varella, Leticia
    Cristofanilli, Massimo
    ONCOTARGETS AND THERAPY, 2023, 16 : 189 - 196
  • [23] Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
    Swain, Sandra M.
    Nunes, Raquel
    Yoshizawa, Carl
    Rothney, Megan
    Sing, Amy P.
    ADVANCES IN THERAPY, 2015, 32 (12) : 1222 - 1236
  • [24] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [25] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    L S Rigter
    C E Loo
    S C Linn
    G S Sonke
    E van Werkhoven
    E H Lips
    H A Warnars
    P K Doll
    A Bruining
    I A Mandjes
    M J Vrancken Peeters
    J Wesseling
    K G Gilhuijs
    S Rodenhuis
    British Journal of Cancer, 2013, 109 : 2965 - 2972
  • [26] Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
    Naoi, Yasuto
    Kishi, Kazuki
    Tsunashima, Ryo
    Shimazu, Kenzo
    Shimomura, Atsushi
    Maruyama, Naomi
    Shimoda, Masafumi
    Kagara, Naofumi
    Baba, Yosuke
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (02) : 299 - 306
  • [27] Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine
    Matikas, Alexios
    Foukakis, Theodoros
    Bergh, Jonas
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 114 : 91 - 101
  • [28] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    Rigter, L. S.
    Loo, C. E.
    Linn, S. C.
    Sonke, G. S.
    van Werkhoven, E.
    Lips, E. H.
    Warnars, H. A.
    Doll, P. K.
    Bruining, A.
    Mandjes, I. A.
    Peeters, M. J. Vrancken
    Wesseling, J.
    Gilhuijs, K. G.
    Rodenhuis, S.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 2965 - 2972
  • [29] Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
    Yasuto Naoi
    Kazuki Kishi
    Ryo Tsunashima
    Kenzo Shimazu
    Atsushi Shimomura
    Naomi Maruyama
    Masafumi Shimoda
    Naofumi Kagara
    Yosuke Baba
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2013, 140 : 299 - 306
  • [30] A predictor model for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
    Fujiki, Yoshitaka
    Yamamoto, Yutaka
    Tomiguchi, Mai
    Sueta, Aiko
    Takeshita, Takashi
    Ibusuki, Mutsuko
    Iwase, Hirotaka
    CANCER SCIENCE, 2018, 109 : 654 - 654
12345